Safety of fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in adolescent patients with psoriasis: Results from a phase 2 trial Liljedahl, M., Abramovits, W., Hoejen, M. N., Teng, J. MOSBY-ELSEVIER. 2019: AB271

View details for Web of Science ID 000482195002261